Literature DB >> 23921727

US National Cancer Institute's new Ras project targets an old foe.

Helen Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23921727     DOI： 10.1038/nm0813-949

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  1 in total

1.  Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Authors:  Gunther Zimmermann; Björn Papke; Shehab Ismail; Nachiket Vartak; Anchal Chandra; Maike Hoffmann; Stephan A Hahn; Gemma Triola; Alfred Wittinghofer; Philippe I H Bastiaens; Herbert Waldmann
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962
  1 in total
  29 in total

1.  AACR Cancer Progress Report 2015.

Authors:  José Baselga; Nina Bhardwaj; Lewis C Cantley; Ronald DeMatteo; Raymond N DuBois; Margaret Foti; Susan M Gapstur; William C Hahn; Lee J Helman; Roy A Jensen; Electra D Paskett; Theodore S Lawrence; Stuart G Lutzker; Eva Szabo
Journal:  Clin Cancer Res       Date:  2015-10-01       Impact factor: 12.531

2.  Drug discovery: Pocket of opportunity.

Authors:  Gideon Bollag; Chao Zhang
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

Review 3.  Searching for the Chokehold of NRAS Mutant Melanoma.

Authors:  Christian Posch; Igor Vujic; Babak Monshi; Martina Sanlorenzo; Felix Weihsengruber; Klemens Rappersberger; Susana Ortiz-Urda
Journal:  J Invest Dermatol       Date:  2016-05-07       Impact factor: 8.551

4.  Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies.

Authors:  Andrew M Waters; Irem Ozkan-Dagliyan; Angelina V Vaseva; Nicole Fer; Leslie A Strathern; G Aaron Hobbs; Basile Tessier-Cloutier; William K Gillette; Rachel Bagni; Gordon R Whiteley; James L Hartley; Frank McCormick; Adrienne D Cox; Peter J Houghton; David G Huntsman; Mark R Philips; Channing J Der
Journal:  Sci Signal       Date:  2017-09-26       Impact factor: 8.192

Review 5.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

6.  Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.

Authors:  Russell Spencer-Smith; Lie Li; Sheela Prasad; Akiko Koide; Shohei Koide; John P O'Bryan
Journal:  Small GTPases       Date:  2017-12-31

7.  NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.

Authors:  Ann-Kathrin Eisfeld; Sebastian Schwind; Kevin W Hoag; Christopher J Walker; Sandya Liyanarachchi; Ravi Patel; Xiaomeng Huang; Joseph Markowitz; Wenrui Duan; Gregory A Otterson; William E Carson; Guido Marcucci; Clara D Bloomfield; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-28       Impact factor: 11.205

Review 8.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Authors:  Ignacio Garrido-Laguna; Manuel Hidalgo
Journal:  Nat Rev Clin Oncol       Date:  2015-03-31       Impact factor: 66.675

Review 9.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

10.  Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma.

Authors:  Weiying Zhang; Nivedita Nandakumar; Yuhao Shi; Mark Manzano; Alias Smith; Garrett Graham; Swati Gupta; Eveline E Vietsch; Sean Z Laughlin; Mandheer Wadhwa; Mahandranauth Chetram; Mrinmayi Joshi; Fen Wang; Bhaskar Kallakury; Jeffrey Toretsky; Anton Wellstein; Chunling Yi
Journal:  Sci Signal       Date:  2014-05-06       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.